FONAR Corporation
NASDAQ:FONRMedical - Devices
+$0.00 today
- Market cap
- $117.76M
- Beta
- 0.95
- P/E (TTM)
- 17.6
- EPS (TTM)
- $1.08
Volume 0.00M
Average 0.08M
FONR Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
FONAR CorporationNASDAQ: FONR
Accounts Receivables · Q3 FY2026 · quarter ended Mar 2026
Accounts receivables declines year over year
Q3 FY2026 accounts receivables of $3.05M (cash outflow) fell 54.6% year over year, behind the -27.6% change in trailing-twelve-month accounts receivables. Sequentially, it rose 288.9% from the prior quarter. Over 3 fiscal years it compounded at +17.3% a year.
Context
- Accounts receivables amounted to 8.6% of revenue in FY2025, down 2.7 pp from a year earlier.
- Accounts receivables grew in size in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -54.6% toward the trailing-twelve-month pace of -27.6%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- (8.98M) USD
- Year-over-year change
- +22.7%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-06-30 | (8.98M) | +22.7% |
| FY2024 | 2024-06-30 | (11.62M) | -43.1% |
| FY2023 | 2023-06-30 | (8.12M) | -46.1% |
| FY2022 | 2022-06-30 | (5.56M) | +53.3% |
| FY2021 | 2021-06-30 | (11.91M) | — |
Accounts Receivables vs competitors
How FONR compares with its peers on the latest reported figures
- Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -27.6% is the 5th highest of 8, against a peer median of +162.7%.
- Accounts receivables amounts to 6.9% of revenue for FONR, versus a peer median of 4.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $7.22M USD | -27.6% | +17.3% | 6.9% | |
| LTM Mar 2026 | $3.09M USD | +162.7% | — | 4.3% | |
| LTM Mar 2026 | $3M USD | +188.4% | — | 3.4% | |
| LTM Mar 2026 | €1.95M EUR | +3826.6% | — | 6648.5% | |
| LTM Mar 2026 | $1.47M USD | +242.9% | — | 9.6% | |
| LTM Mar 2026 | $1.31M USD | -404.9% | — | 2.3% | |
| LTM Mar 2026 | $522K USD | -769.2% | — | — | |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | $183K USD | -87.7% | — | — |
| Peer median (excluding FONR) | — | +162.7% | — | 4.3% | |
Competitors are the stored peer set for FONR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Jun 2021 | FY2022 Jun 2022 | FY2023 Jun 2023 | FY2024 Jun 2024 | FY2025 Jun 2025 |
|---|---|---|---|---|---|
| Net Income | 13.67M | 17.23M | 12.13M | 14.1M | 10.67M |
| Depreciation & Amortization | 5.54M | 8.54M | 8.8M | 4.6M | 4.7M |
| Deferred Income Tax | 3.53M | 3.09M | 2.98M | 2.8M | 823.66K |
| Stock-Based Compensation | 83.28K | 0 | 0 | 0 | 0 |
| Change in Working Capital | (11.26M) | (14.21M) | (15.17M) | (8.62M) | (8.19M) |
| Accounts Receivables | (11.91M) | (5.56M) | (8.12M) | (11.62M) | (8.98M) |
| Inventory | (14.65K) | (696.4K) | (209.85K) | (145.78K) | (97.24K) |
| Accounts Payables | (99.22K) | (314.77K) | 19.69K | 276.67K | (553.56K) |
| Other Working Capital | 762.59K | (7.64M) | (6.86M) | 2.87M | 1.44M |
| Other Non-Cash Items | 7.53M | 642.77K | 5.73M | 1.22M | 3.26M |
| Operating Cash Flow | 19.09M | 15.3M | 14.47M | 14.09M | 11.26M |
| Capital Expenditures | (4.82M) | (4.63M) | (4.34M) | (822.85K) | (3.82M) |
| Acquisitions (Net) | 0 | (546K) | 0 | 0 | 0 |
| Purchases of Investments | (293) | (149) | (473) | (103.3K) | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (163.71K) | (87.88K) | (119.57K) | 42.53K | (9.72K) |
| Investing Cash Flow | (4.82M) | (5.18M) | (4.34M) | (850.74K) | (3.8M) |
| Debt Repayment | (40.34K) | (37.24K) | (36.62K) | (44.9K) | (113.94K) |
| Common Stock Issued | 0 | 0 | 0 | 0 | 0 |
| Common Stock Repurchased | 0 | 0 | (1.76M) | (2.51M) | (1.81M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (6.57M) | (5.82M) | (5.78M) | (5.63M) | (5.55M) |
| Financing Cash Flow | (6.61M) | (5.86M) | (7.57M) | (8.18M) | (7.47M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 7.66M | 4.26M | 2.56M | 5.06M | (7.56K) |
| Free Cash Flow | 14.27M | 10.67M | 10.13M | 13.27M | 7.45M |
FONAR Corporation
NASDAQ:FONR
Intrinsic Alpha fair value
Locked
Current Price
$19.09
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.